Africa CDC warns India: vaccine nationalism threatens global pandemic control

In mid-April 2021, as India grappled with a devastating surge in COVID-19 infections, the continent of Africa faced a different kind of crisis: a vaccine supply that had nearly run dry. John Nkengasong, director of the Africa Centers for Disease Control and Prevention, stood before reporters in Nairobi with a blunt warning. India, he said, needed to understand that it was not isolated from the rest of the world. By restricting vaccine exports to manage its own outbreak, India was gambling with the health of 1.3 billion Africans who had barely begun their vaccination campaigns.

The math was stark. Across Africa's 54 countries, just under 14 million vaccine doses had been administered. Some nations—Ghana and Rwanda among them—had already used up their initial allocations and faced an uncertain wait for second doses. The continent was aiming to vaccinate 750 million people over two years, but at the current pace, that timeline seemed almost fantastical. Meanwhile, India, a major vaccine manufacturer and the primary supplier to COVAX, the United Nations-backed initiative designed to deliver shots to the world's poorest countries, had begun holding back exports as its own caseload spiraled.

Nkengasong's argument was epidemiological as much as moral. If wealthy nations finished vaccinating their populations while Africa remained largely unprotected, new variants would inevitably emerge in the unvaccinated masses. Those variants would then circle back and undermine the vaccination efforts of countries that thought they had already secured their safety. "If you finish vaccinating your people before Africa or other parts of the world, you have not done yourself any justice," he said. The virus, in other words, did not respect borders or economic status.

The uncertainty was suffocating. A WHO vaccination official in Africa, Richard Mihigo, told reporters that COVAX was in "intensive discussions" with India and the Serum Institute of India to maintain some supply in April and resume full shipments by May or June. But those were hopes, not promises. For the second doses that African nations desperately needed in those months, there was no clear timeline and no firm commitment on quantities. The situation was, as Nkengasong put it, "very dicey."

Complicating matters further were new safety concerns about the very vaccines available to Africa. South Africa, the continent's hardest-hit nation with 4.3 million confirmed infections, suspended use of the Johnson & Johnson vaccine after preliminary reports of rare blood clots emerged. Weeks earlier, it had abandoned plans to use AstraZeneca on health care workers after a small study suggested the vaccine offered minimal protection against mild to moderate illness caused by the variant dominant in the country. These were not abstract concerns—they were real obstacles to vaccination campaigns that were already fragile.

The global inequity was staggering. Just one in every 500 vaccine doses administered worldwide had gone to low-income countries. Africa, home to more than a billion people, had received a fraction of what wealthier nations had secured for themselves. And now, as variants spread—19 African countries had reported the British variant, 18 the South African variant—the continent faced the prospect of watching the pandemic evolve in real time while remaining largely unvaccinated.

Nkengasong urged caution about second-dose delays but also insisted that available vaccines be used before expiration. The Serum Institute had suggested doses could be extended beyond their labeled dates, but he wanted no delays, no hesitation. Every dose mattered. As April turned toward May, Africa waited—for India to stabilize, for COVAX to deliver, for the world to remember that a pandemic anywhere was a threat everywhere.